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Chemogenetic studies with the ligand clozapine N-oxide (CNO) are predicated upon
the assumption that CNO is devoid of actions at natural neuroreceptors. However,
recent evidence shows that CNO may be converted back to clozapine (CLZ) in vivo,
which could yield plasma concentrations that may be sufficient to occupy inter alia
dopamine D2/3 and serotonin 5HT2A receptors in living brain. To test this phenomenon,
we measured striatal dopamine D2/3 receptor occupancy with [18F]fallypride PET
and serotonin 5HT2A occupancy ex vivo using [18F]MH.MZ. We found a CNO dose-
dependent effect on the availability of both neuroreceptor sites. In parallel MR
spectroscopy experiments, we found that CNO reduced creatine + phosphcreatine
(Cr+PCr) and increased N-acetylaspartate + N-acetylaspartylglutamate (NAA+NAAG)
signals in the prefrontal cortex, and also reduced the glutamate signal in dorsal striatum,
with peak effect at 2 mg/kg. Thus, our findings suggest that conversion of CNO to CLZ in
living rats imparts significant occupancy at endogenous neuroreceptors and significant
changes to neurometabolite levels.
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INTRODUCTION
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are bioengineered from
the muscarinic G protein-coupled receptor and have no natural ligand, but possess high agonistic
affinity for the exogenous ligand clozapine N-oxide (CNO) (Armbruster et al., 2007). These
receptors can be expressed with coupling to the Gq, Gi, and Gs signal transduction pathways, thus
affording a powerful tool to study pathway-specific G-protein function of brain and peripheral
nerves. CNO is a major metabolite of clozapine (CLZ) (Baldessarini et al., 1993), which is a widely
used atypical antipsychotic medication with binding to a broad range of neuroreceptors, namely
dopamine D4, D2, D3, serotonin 5-HT2A, 5-HT2C, muscarinic M1, M2, M3, M4, adrenergic α1 and
α2, as well as histamine H1 receptors. Furthermore, CLZ is also a high affinity agonist ligand for
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the DREADDs (Schotte et al., 1993; Bymaster et al., 1996;
Zhang and Bymaster, 1999; Chen et al., 2015). While CNO
is considered devoid of any specific binding other than to
DREADD, recent studies suggest that CNO can convert back
to CLZ in living rats (MacLaren et al., 2016) and dogs (Meier,
1975). Although CLZ was not detectable in plasma after a low
administered dose of CNO (1 mg/kg) (Jann et al., 1993), a
high dose of CNO (20 mg/kg) evoked measurable formation
of plasma CLZ (Lin et al., 1996). CLZ has high uptake in rat
brain, with a brain-to-plasma ratio of 24:1 (Baldessarini et al.,
1993), predicting that much of the CLZ produced from CNO
metabolism will accumulate in brain. In contrast, untransformed
CNO has low permeability to the rat blood brain barrier (Gomez
et al., 2017) and is therefore mainly confined to the plasma
compartment of CLZ-treated rats (Baldessarini et al., 1993).
Given this background, it has been suggested that the action
of CNO on DREADDs in the brain is obtained solely via its
metabolite CLZ (Gomez et al., 2017).
If CLZ is indeed the in vivo DREADD activator, it becomes
imperative to confirm that a usual dose of CNO (or CLZ) does
not interfere with other binding sites. CLZ is known to have
in vivo occupancy at brain dopamine D2/3 receptors (Mukherjee
et al., 2001; Olsen et al., 2008) as well as serotonin 5-HT2A
receptors in direct proportion to plasma concentrations (Knauer
et al., 2008). Furthermore, CLZ treatment has been reported
to alter in vivo levels of glutamate (Glu), N-acetylaspartate
(NAA) and N-acetylaspartylglutamate (NAAG), albeit without
direct relationship to the plasma CLZ concentration (Lidsky
et al., 1993; Yamamoto and Cooperman, 1994; Arun et al.,
2008; Krivoy et al., 2017). Therefore, brain concentrations of
these neurochemcials can serve as surrogate indicators of central
actions of the CNO metabolite.
To test our hypothesis that metabolism of CNO to CLZ
in vivo induces blockade of D2/3 and 5-HT2A receptors, we
examined the CNO-induced in vivo receptor occupancy in
conjunction with two available PET tracers, the dopamine
D2/3 radioligand [18F]fallypride and the serotonin 5-HT2A
receptor radioligand [18F]MH.MZ. We chose to inject
CNO 20 min before experimental procedures to ensure
translatability with previously published animal studies
(Agulhon et al., 2013; Urban et al., 2015; Baslow et al.,
2016). Furthermore, to test for effects of the treatment
on neurometabolites, we also examined neurochemical
changes in the prefrontal cortex and striatum using Magnetic
Resonance Spectroscopy (MRS). These experiments provide
relevant information about dose-dependent effects of CNO
at neuroreceptors in Long-Evans rats and may call for re-
interpretation of some DREADD experiments published prior




Long-Evans rats were bred at the Department of Experimental
Medicine Biocenter (AEM, University of Copenhagen). The rats
were housed in groups of 2–4 animals per cage in a climate-
controlled rodent facility with 12 h/12 h light/dark cycle. The
rats were fed ad libitum and had free access to water. Female
rats were used for the PET and MRS scans, while both male
and female rats where used in the ex vivo experiment. All
procedures were conducted in accordance with the FELASA
guidelines for animal research and with approval from The
Danish Animal Experiments Inspectorate (license number: 2016-
15-0201-01031) as well as the Department of Experimental
Medicine, University of Copenhagen.
Chemicals
Radiochemicals were produced in house as described below.
CNO was provided by BioNordika Denmark and all other
chemicals were from standard vendors.
Radiosyntheses of [18F]Fallypride
[18F]Fallypride was synthesized as previously described (Piel
et al., 2014). In short, the tosyl-fallypride precursor (0.2 mg)
in 1 mL dimethylsulfoxide (DMSO) was added to the dried
[18F]KF-K222 complex via automated injection and was heated to
150◦C for 20 min. The product was then purified using a semi-
preparative HPLC method (Luna, 10 µm, C-18 column; 20%
ethanol in 0.1% phosphoric acid in water-retention time 10 min).
Purity of the isolated product was confirmed by analytical
HPLC (Kinetic, C-18 with pre-column; 25% acetonitrile in
0.1% phosphoric acid in water; 1.5 mL/min – retention time
1.12 min). The radiochemical purity of [18F]fallypride was 99%
and molar activity was 68 GBq/µmol. The resulting ethanol tracer
solutions were diluted to the necessary volume in 0.1 M sterile
phosphate buffer.
Radiosyntheses of [18F]MH.MZ
[18F]MH.MZ was synthesized as previously described (Herth
et al., 2008). In brief, MDL 105,725 was alkylated with 2-
[18F]fluoroethyl tosylate ([18F]FEtTos) using an automated
synthesis module. Identity of [18F]MH.MZ was confirmed by co-
elution with non-radioactive [19F]MH.MZ standard on analytical
HPLC (Luna 5 µm, C-18 column, acetonitrile/water/TFA
40/60/0.1 (v/v) – retention time 9.5 min). The radiochemical
purity of [18F]MH.MZ was > 97% and molar activity was
22 GBq/µmol. The resulting ethanol tracer solutions were diluted
to the necessary volume in 0.1 M sterile phosphate buffer.
Dopamine D2 Receptor Occupancy
Five groups of female rats first received s.c. injections of 5%
DMSO/saline vehicle (n = 16) or CNO [0.5 (n = 8), 2 (n = 6),
5 (n = 6) or 8 (n = 6) mg/kg] in 5% DMSO/saline followed 20 min
later by an i.v. injection of approximately 10 MBq [18F]fallypride.
The rats were anesthetized 40 min later with isoflurane (2–
2.5% in oxygen) and placed in a homemade 2 × 2 rat insert
in the aperture of a Siemens HRRT (High Resolution Research
Tomograph) scanner (Keller et al., 2016) for a 45-min dynamic
emission scan followed by a point source transmission scan
(Tantawy et al., 2009, 2011). Scatter and attenuation corrections
were performed, and the reconstructed PET image data were first
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cropped manually to a head-only image in PMOD v3.7, followed
by motion correction with the PFUSEIT tool and summation
for the purposes of registration. The images were corrected for
body weight and injected dose using in-house code in MATLAB
R2013a. The automatic co-registration with a tracer-specific PET
template as target was executed in FSL 5.0.11 with the flirt
command using the normalized correlation cost function with
12 degrees of freedom. A modified Logan reference tissue model
with the cerebellum as reference region was used to calculate
the binding potential (BPND) in volumes of interest (VOIs) of
bilateral dorsal or ventral striatum, as well as prefrontal cortex
(Tantawy et al., 2009). Percent occupancy was calculated as the
percent of the BPND or specific binding ratio at a given dose of
CNO in relation to vehicle administration.
Serotonin 5-HT2A Receptor Occupancy
Five groups of male (m, round) and female (f, triangle) rats first
received s.c. injections of 5% DMSO/saline vehicle (n = 7, 4m/3f)
or CNO (0.5 (n = 8, 5m/3f), 2 (n = 8, 6m/2f), 5 (n = 7, 4m/3f)
or 8 (n = 5, 5 m) mg/kg) in 5% DMSO/saline followed 20 min
later by an i.v. injection of 200 µL [18F]MH.MZ, approximately
10 MBq at the time of first injection. [18F]MH.MZ-injected rats
were killed by decapitation at 60 min of tracer circulation, and
the extracted brain was dissected into weighed frontal cortex and
cerebellum samples. The concentration of tracer was measured
in a Packard Cobra gamma counter, calculated per gram of
tissue, and reported as specific binding ratio ((frontal cortex –
cerebellum)/cerebellum). Percent occupancy was calculated as
the percent of the BPND or specific binding ratio at a given dose
of CNO in relation to vehicle administration.
Glutamate Levels
Female rats (not the same rats as above) were anesthetized with
isoflurane in oxygen, with induction at 3% and maintenance
at 1.25–2.0% isoflurane during scans. All rats were scanned in
the prefrontal cortex (30 min after) and in the right dorsal
striatum (60 min after) after receiving s.c. injections of 5%
DMSO/saline vehicle (n = 11/12) or CNO (0.5 (n = 4), 2 (n = 8),
or 5 (n = 4) mg/kg) in 5% DMSO/saline. Rats were scanned
at baseline and after treatment (excepting four of the 2 mg/kg
CNO treated animals, which were only scanned after treatment,
and one scan that failed in prefrontal cortex). Structural images
were obtained with TurboRARE sequences. Local magnetic field
homogeneity was adjusted in a 2 × 3 × 3 mm/18 µL VOI
in the prefrontal cortex and in a 3 × 3 × 3 mm/27 µL VOI
in the right dorsal striatum using FASTMAP. The MRS/1H-
NMR spectrum was obtained using a STEAM (Stimulated Echo
Acquisition Mode) sequence (TE: 3 ms, TR: 4000 ms, 400
ave, 4096 data points) with outer volume and VAPOR water
suppression. All spectroscopy scans were performed on a Bruker
BioSpec 94/30 USR MRI system (9.4 T, 30 cm bore, Bruker,
Ettlingen, Germany) using a quadrature 86 mm rat body volume
transmitter coil and 4 channel phase array receiver coil (Bruker,
Ettlingen, Germany) with Paravision 5.3 software. MRS data was
quantified with LCModel (Provencher, 1993) using simulated
baseline and macro-molecule baseline.
Statistics
All data are expressed as mean ± SD as calculated in
Graphpad Prism v7.03. Significance of receptor occupancy
changes was calculated with a one-way ANOVA with Dunnet’s
multiple corrections test; ANOVA summary is attached in
the Supplementary Material. Significance in neurometabolite
levels to MRS was calculated using a two-way ANOVA with
Sidak’s multiple corrections test. Significant levels are as follows:




[18F]Fallypride, which binds with high affinity (KD: 0.03 nM)
to dopamine D2/3 receptors in vitro (Mukherjee et al., 1995),
is extensively used to measure dopamine or drug occupancy
in dopamine D2/3 receptor rich regions of the living brain.
After vehicle treatment, [18F]fallypride BPND was 0.72 ± 0.18
in the prefrontal cortex, 4.83 ± 0.91 in the dorsal striatum and
3.11± 0.65 in the ventral striatum (Figure 1). Pretreatment with
0.5 mg/kg CNO did not change the [18F]fallypride BPND in any
region, but 2 mg/kg reduced BPND by 36% in the prefrontal
cortex (BPND at 2 mg/kg CNO: 0.46 ± 0.14, Figures 1B,C).
The effects of CNO 2 mg/kg in the prefrontal cortex were not
evident at 5 and 8 mg/kg CNO. 5 mg/kg did not significantly
affect the BPND in any region, whereas 8 mg/kg CNO reduced
[18F]fallypride BPND by 34% in the dorsal and by 26% in ventral
striatum (BPND at 8 mg/kg CNO: 3.19 ± 0.57, Figures 1D,E
and 2.29 ± 0.25, respectively, Figures 1F,G). There was a
significant difference of BPND between CNO treatments in
the prefrontal cortex and dorsal striatum as calculated with
an ordinary one-way ANOVA (Supplementary Tables 1–3).
Furthermore, pretreatment with 0.5 mg/kg CNO did not
significantly change the specific binding ratio of [18F]MH.MZ
(a serotonin 5HT2A receptor ligand), whereas pretreatment with
2, 5 and 8 mg/kg reduced the binding ratio by 15, 9, and 14%,
respectively (Figures 2A,B). There was a significant effect of
treatment between groups using an ordinary one-way ANOVA
(Supplementary Table 4), although post hoc Dunnett’s test
revealed that no single dose significantly altered the binding ratio
relative to the vehicle group (Supplementary Table 4).
Clozapine N-Oxide Reduces Striatal
Glutamate Levels
Baseline metabolite concentration of creatine+ phosphocreatine
(Cr+PCr), glutamine (Gln), glutamate (Glu), N-acetylaspartate
+ N-acetylaspartate glutamate (NAA + NAAG) and total
glutamine + glutamate (Gln + Glu) were quantified from
the obtained MR spectrum (Figure 3C) in prefrontal cortex
(Figure 3D) and dorsal striatum (Figure 3E), as reported in detail
in the Supplementary Material (Supplementary Table 5): GABA
and glucose could not be reliably quantified in all rats using
this voxel size and scan sequence. A representative spectrum
and voxel placement are presented in Figures 3A–C. There was
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FIGURE 1 | [18F]Fallypride binding in the rat prefrontal cortex and striatal regions (A), 5 mg/kg Clozapine N-oxide (CNO) induced a noticeable decline in receptor
availability in the same rat (A). CNO induced occupancy on a group level at the dopamine D2/3 receptors in the prefrontal cortex (B,C) as well as dorsal (D,E) and
ventral (F,G) striatum. Horizontal lines and ∗represents a significant effect of treatments, as measured with a one-way ANOVA (∗p < 0.05, ∗∗p < 0.01
and ∗∗∗p < 0.001).
FIGURE 2 | Serotonin 5HT2A ex vivo specific binding ration of [18F]MH.MZ
and the CNO induced occupancy. Male rats are round and females are
triangular. Horizontal line and ∗represents a significant effect of treatments, as
measured with a one-way ANOVA (∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001).
no effect of pretreatment with 0.5 mg/kg CNO in comparison
to vehicle in either the prefrontal cortex or dorsal striatum.
However, pretreatment with 2 mg/kg CNO induced a significant
decrease in Cr+PCr (–11%, 5.32 ± 0.19 mM, p = 0.0032)
and an increase in NAA+NAAG (14%, 5.89 ± 0.27 mM,
p = 0.0095) concentrations in the prefrontal cortex. Furthermore,
pretreatment with 2 mg/kg CNO also induced decreased
glutamate (–9%, 5.79 ± 0.82 mM, p = 0.0251) and total
glutamate + glutamine (–7%, 8.34 ± 0.84 mM, p = 0.0080)
concentrations in the dorsal striatum (Statistics are reported in
Supplementary Tables 7, 8).
DISCUSSION
The results confirm our hypothesis that CNO induces occupancy
at dopamine D2/3 and serotonin 5-HT2A receptors in Long-Evans
rats, albeit without providing direct insight into the basis of
this occupancy. It has been reported that CNO converts to CLZ
in vivo, producing a peak CLZ plasma concentration between 10
and 30 min (Meier, 1975; MacLaren et al., 2016). Administration
of CNO at a dose of 5 mg/kg generated 0.28µM (about 92 ng/mL)
CLZ in the plasma (MacLaren et al., 2016; Gomez et al., 2017)
at 30 min after treatment. Baldessarini et al. found a similar
CLZ concentration 1 h after an acute dose of 10 mg/kg CLZ
i.p (Baldessarini et al., 1993). There is a two-phase correlation
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FIGURE 3 | Neurometabolite concentrations as measured in vivo using MR spectroscopy. Cubic voxels 18 µL in the prefrontal cortex (A) and 27 µL dorsal striatum
(B). A sample spectrum (C) from the voxel in the dorsal striatum and metabolite concentrations in the voxels following pretreatments with different doses of CNO in
the prefrontal cortex (D) and in the dorsal striatum (E). ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 two-way ANOVA with Sidak’s multiple corrects test.
between plasma CLZ levels and the occupancy at dopamine D2/3
receptors (Mukherjee et al., 2001; Olsen et al., 2008); the plateau
for the first phase occurred with doses in the range of 0.1 to
40 mg/kg CLZ i.p., These doses provoked a striatal occupancy of
20–50%, which is often considered as the therapeutic window for
CLZ for the treatment of schizophrenia. In a rat [18F]fallypride
PET study, Mukherjee et al. (2001) found a 30% occupancy level
at 2 h after administration of 10 mg/kg CLZ. Although the exact
occupancy by CLZ is dependent on the time of pretreatment and
PET acquisition (Olsen et al., 2008), there is general agreement
with our findings for CNO, which induced 26–39% dopamine
D2/3 occupancy in the striatal regions at 1 h after injection of
8 mg/kg CNO. CLZ is known to induce dopamine release in the
medial prefrontal cortex (Rowley et al., 2000) to a higher extent
than in the dorsal striatum (Karoum and Egan, 1992). Therefore,
it is likely that the inverted u-shape of CLZ-induced occupancy
in the prefrontal cortex arises from dopamine release.
As mentioned above, the affinity of CNO for 5-HT2A receptors
(ID50 1–2 mg/kg) exceeds that for dopamine D2/3 receptors
(ID50 20 mg/kg) (Schotte et al., 1993; Zhang and Bymaster,
1999). Present results support this by showing cortical 5-HT2A
receptor occupancy at low doses (Figures 2A,B) compared
with D2/3 in the striatal regions. Knauer et al. found a
CLZ dose-dependent occupancy of 5-HT2A receptors, with a
plasma concentration of 92 ng/mL giving 50–75% occupancy
(Knauer et al., 2008). However, several questions arise from these
[18F]MH.MZ experiments. First, CLZ occupancy of [18F]MH.MZ
binding sites has not hitherto been established, so there is no
direct literature we can compare to. Second, we do not know
if CLZ and [18F]MH.MZ share the same binding site on the
5HT2A receptors. We choose to include this experimental data
because it provides some explanation as to why we detected
effects on neurochemicals and D2/3 receptor occupancy at a CNO
dose of 2 mg/kg. As previously noted, CLZ also bind to other
neuroreceptors with higher affinity than toward dopamine D2
receptors. For the present, we can only assume that occupancy
of these receptors will likely exceed that of the D2 receptors.
In vivo evidence of acute CLZ effects on neurometabolite levels
is sparsely documented, although we know that chronic clozapine
treatment does effect levels of glutamate, glutamine, creatine,
NAA+NAAG and other metabolites (McLoughlin et al., 2009).
Likewise, CLZ is without effect on the activity of nGCP II, the
enzyme that catabolizes NAAG to glutamate (Flores and Coyle,
2003), or creatine kinase, the enzyme that catabolizes creatine
to phosphocreatine (Assis et al., 2007; Scaini et al., 2013). The
effects of CLZ on glutamate levels and glutamate signaling are
particularly ambiguous. Some authors have reported that acute
CLZ inhibited corticostriatal signaling and lowered glutamate
release in PFC terminals (Lidsky et al., 1993; Yang and Wang,
2005), while others have reported increased glutamate release in
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the PFC (Tanahashi et al., 2012). Interestingly, selective 5-HT2A
antagonists decrease glutamate concentrations in the dorsal
striatum (Ansah et al., 2011), likely by blockade of the 5-HT2A
receptors, which are mainly located on the somatic and dendritic
region of corticostriatal pyramidal neurons (Miner et al., 2003).
We suppose that 5-HT2A inhibition of glutamate release in dorsal
striatum could precede the glutamate release potentiated by other
means, as the inhibitory effect on glutamate was evident with
a CNO dose (2 mg/kg) lower than that causing discernible
occupancy at D2/3 receptors (5 mg/kg). Such a bidirectional
activation and inhibition could explain the effects that we and
others observe, but further studies are needed to elucidate the
neurochemical basis of the observed effects of CNO and to
confirm that these effects are indeed precipitated by conversion
of CNO to CLZ in the living rodent. However, these data confirm
that CNO is not a neurochemically inert drug and call for
caution in the attribution of effects of CNO in the context of
chemogenetic (DREADD) ligand studies.
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